Traditional peptide synthesis relies on an orthogonal protecting group strategy, employing excess coupling reagents and generating significant waste. To enhance sustainability, our collaboration with PeptiSystems explores the potential of flow-through column technology. Initial experiments show promising results, reducing amino acid and coupling agent consumption, while maintaining comparable crude purities. In addition, coupling times were decreased, and the PMI significantly improved using high loaded resins without compromising the overall process. This initiative aligns with Corden Pharma’s commitment to greener and more efficient manufacturing.
